Literature DB >> 15957199

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year followup.

Daniel Schuepbach1, S Kristian Hill, Richard D Sanders, Daniel Hell, Matcheri S Keshavan, John A Sweeney.   

Abstract

Studying neuroleptic-naive first episode schizophrenia is a strategy for investigating clinical and neuropsychological abnormalities at a very early phase of the disease without confounding influences of illness duration and medication effects. We examined the clinical and neuropsychological time course over 2 years in 32 neuroleptic-naive first episode patients (20 males, 12 females) and 21 healthy individuals with similar sociodemographic characteristics. Early treatment-induced reduction of negative symptoms predicted superior cognitive performance throughout followup in the domains of verbal fluency, attention, and non-verbal learning and memory. There were no associations between psychotic or disorganized symptoms and cognitive variables. These findings suggest an important relationship between treatment efficacy of antipsychotic medication and the longer term course of cognitive deficits in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15957199     DOI: 10.1093/oxfordjournals.schbul.a007136

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  6 in total

Review 1.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

2.  Impaired associative inference in patients with schizophrenia.

Authors:  Kristan Armstrong; Samet Kose; Lisa Williams; Austin Woolard; Stephan Heckers
Journal:  Schizophr Bull       Date:  2010-12-06       Impact factor: 9.306

3.  Multivariate Relationships Between Cognition and Brain Anatomy Across the Psychosis Spectrum.

Authors:  Amanda L Rodrigue; Jennifer E McDowell; Neeraj Tandon; Matcheri S Keshavan; Carol A Tamminga; Godfrey D Pearlson; John A Sweeney; Robert D Gibbons; Brett A Clementz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-03-31

4.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

5.  Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia.

Authors:  S Kristian Hill; James L Reilly; Margret S H Harris; Tin Khine; John A Sweeney
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

6.  Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Zhen-Hua Chen; Gao-Hua Wang; Xiao-Ping Wang; Ren-Yun Chen; Hui-Lin Wang; Ming-Hua Yang; Yun-Xiang Huo; Hong-Bing Mei
Journal:  Curr Ther Res Clin Exp       Date:  2008-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.